Oncolytics Aligns with FDA on Registrational Path for Pelareorep in Colorectal Cancer
ONCY is trading near its 52-week low of $0.73 (14% above the low) on light trading volume (0.4× avg).
Summary
Oncolytics received FDA written feedback aligning on a potential pivotal Part B expansion of its REO 033 colorectal cancer study, offering a potential accelerated approval pathway based on objective response rate and progression-free survival.
Key Events · Product Development and Regulatory · ONCY
-
FDA Alignment on Pivotal Path
FDA written feedback supports a potential pivotal Part B expansion of the ongoing REO 033 study in second-line RAS-mutant MSS colorectal cancer.
-
Accelerated Approval Potential
Proposed pathway offers potential accelerated approval based on objective response rate, with progression-free survival supporting full approval.
-
Regulatory Strategy Shift
Company elected to forego its scheduled Type D meeting and pursue an End-of-Phase meeting with the FDA as the program advances.
-
Next Milestone
Oncolytics plans to launch Part B start-up activities as soon as positive interim Part A data are available, minimizing time to pivotal expansion.
Analysis · ONCY · Life Sciences
The FDA's written feedback validates a potential accelerated approval pathway for pelareorep in second-line RAS-mutant MSS colorectal cancer. This is a major regulatory milestone that could significantly shorten the path to market for the company's lead asset. The company can now plan a pivotal Part B expansion of the ongoing REO 033 study, with objective response rate supporting accelerated approval and progression-free survival supporting full approval. This de-risks the clinical development program and provides a clear regulatory roadmap, which is especially critical given the company's going concern status and recent Nasdaq delisting notice.
At the time of this filing, ONCY was trading at $0.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $104.9M. The 52-week trading range was $0.73 to $1.51. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.